161 related articles for article (PubMed ID: 24449780)
1. Post-β-lactamase-inhibitor effect of tazobactam in combination with ceftolozane on extended-spectrum-β-lactamase-producing strains.
Sader HS; Rhomberg PR; Jones RN
Antimicrob Agents Chemother; 2014; 58(4):2434-7. PubMed ID: 24449780
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of Ceftolozane plus Tazobactam Studied in an In Vitro Pharmacokinetic Model of Infection.
MacGowan AP; Noel AR; Tomaselli SG; Nicholls D; Bowker KE
Antimicrob Agents Chemother; 2016 Jan; 60(1):515-21. PubMed ID: 26552975
[TBL] [Abstract][Full Text] [Related]
3. Combinatorial Pharmacodynamics of Ceftolozane-Tazobactam against Genotypically Defined β-Lactamase-Producing Escherichia coli: Insights into the Pharmacokinetics/Pharmacodynamics of β-Lactam-β-Lactamase Inhibitor Combinations.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Antimicrob Agents Chemother; 2016 Apr; 60(4):1967-73. PubMed ID: 26729494
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.
Vanscoy B; Mendes RE; McCauley J; Bhavnani SM; Bulik CC; Okusanya OO; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2013 Dec; 57(12):5924-30. PubMed ID: 24041895
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftolozane-tazobactam as determined by broth dilution and agar diffusion assays against recent U.S. Escherichia coli isolates from 2010 to 2011 carrying CTX-M-type extended-spectrum β-lactamases.
Estabrook M; Bussell B; Clugston SL; Bush K
J Clin Microbiol; 2014 Nov; 52(11):4049-52. PubMed ID: 25143578
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model.
VanScoy B; Mendes RE; Nicasio AM; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2013 Jun; 57(6):2809-14. PubMed ID: 23629705
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Melchers MJ; van Mil AC; Mouton JW
Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics of Ceftolozane Combined with Tazobactam against Enterobacteriaceae in a Neutropenic Mouse Thigh Model.
Melchers MJ; Mavridou E; van Mil AC; Lagarde C; Mouton JW
Antimicrob Agents Chemother; 2016 Dec; 60(12):7272-7279. PubMed ID: 27671063
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Piperacillin in an In Vitro Infection Model.
Nicasio AM; VanScoy BD; Mendes RE; Castanheira M; Bulik CC; Okusanya OO; Bhavnani SM; Forrest A; Jones RN; Friedrich LV; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2016 Apr; 60(4):2075-80. PubMed ID: 26787689
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012).
Sader HS; Farrell DJ; Flamm RK; Jones RN
J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics-Pharmacodynamics of Tazobactam in Combination with Cefepime in an
VanScoy BD; Tenero D; Turner S; Livermore DM; McCauley J; Conde H; Bhavnani SM; Rubino CM; Ambrose PG
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28947475
[TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.
Cho JC; Fiorenza MA; Estrada SJ
Pharmacotherapy; 2015 Jul; 35(7):701-15. PubMed ID: 26133315
[TBL] [Abstract][Full Text] [Related]
15. Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Canovas J; Petitjean G; Chau F; Le Monnier A; Fantin B; Lefort A
Clin Microbiol Infect; 2020 Oct; 26(10):1416.e5-1416.e9. PubMed ID: 32629024
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
17. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
18. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
Vanscoy B; Mendes RE; Castanheira M; McCauley J; Bhavnani SM; Forrest A; Jones RN; Okusanya OO; Friedrich LV; Steenbergen J; Ambrose PG
Antimicrob Agents Chemother; 2013 Sep; 57(9):4134-8. PubMed ID: 23774429
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
20. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I
Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
